Posted by Michael Wonder on 21 Mar 2022
NICE recommends elosulfase alfa for routine NHS use for patients with rare life-limiting metabolic disorder
21 March 2022 - NICE has today published final draft guidance recommending elosulfase alfa (Vimizim; BioMarin) for routine use in the NHS for the treatment of mucopolysaccharidosis type 4A (also known as MPS 4A and Morquio A syndrome).
Elosulfase alfa becomes the first disease modifying treatment recommended by NICE for routine NHS use for people with this rare, severely life-limiting condition.
